Iron bisglycinate is gentler on the stomach and better absorbed than other iron supplements.
11 sources: 1 positive, 9 partly, 1 negative.
Researchers say
No researcher counted yet.
Studies show
1 positive, 9 partly, 1 negative
11 papers we read
-
Controlled trial, Nutrients, 2022, PMID 35276810
Positive Study
Read the paper on PubMed →One in particular, ferrous bisglycinate, has been demonstrated to have at least two-fold higher bioavailability and absorption compared to conventional iron salts, including ferrous sulfate and ferrous fumarate, while also resulting in improved oral tolerability during pregnancy [ 6 , 7 ].
-
Trial or observed group, Int J Vitam Nutr Res, 2004, PMID 15743019
Partly Study
Read the paper on PubMed →Finally there is an urgent need for more rigorous efficacy trials designed to define the relative merits of amino acid chelates when compared with bioavailable iron salts such as ferrous sulfate and ferrous fumarate and to determine appropriate fortification levels
-
Controlled trial, Nutr J, 2014, PMID 25023784
Partly Study
Read the paper on PubMed →There were no significant differences between the groups in the presentation of side effects potentially associated to iron supplementation.
-
Trial or observed group, Curr Pediatr Rev, 2018, PMID 29366419
Partly Study
Read the paper on PubMed →In our patients, treatment with iron bisglycinate chelate demonstrated an equivalent haematopoietic response compared to iron sulfate when administered approximately at quarter of the dose: 0.75 mg/kg/day compared to 3 mg/kg/day.
-
Controlled trial, Curr Pediatr Rev, 2018, PMID 30280670
Partly Study
Read the paper on PubMed →However, only the FeBC group showed a significant increase in MCH and ferritin levels compared to baseline.
-
Trial or observed group, Ann Hematol, 2020, PMID 31965272
Partly Study
Read the paper on PubMed →Gain of Hb at 2 and 8 weeks revealed a higher median increase in both ferrous 2 and ferrous 4 groups.
-
Other primary study, J Trace Elem Med Biol, 2020, PMID 32653832
Partly Study
Read the paper on PubMed →A 1 mo intervention with 3 minerals that included iron (36 mg/day) significantly raised ferritin values when the iron was bisglycinate (p < 0.05), but not when it was ferrous sulfate (p > 0.05).
-
Trial or observed group, Clin Nutr ESPEN, 2021, PMID 34857222
Partly Study
Read the paper on PubMed →Side effects of drugs were higher in FeBC group than LF group, and higher in LF with iron group than FeBC group.
-
Controlled trial, J Pregnancy, 2024, PMID 39582678
Partly Study
Read the paper on PubMed →Comparing the three iron formulas in doses that can prevent ID and IDA, ferrous bisglycinate 25 mg iron had the most favourable GI side effect profile, while ferrous fumarate 40 mg iron and ferrous sulphate 50 mg iron had somewhat higher but similar GI side effect profiles.
-
Other primary study, Wiad Lek, 2026, PMID 41759009
Partly Study
Read the paper on PubMed →Dynamic analysis of clinical symptoms and haematologic indicators in both groups demonstrated a significant decrease in subjective complaints, accompanied by normalization of laboratory parameters, confirming the positive effects of the interventions.
-
Other primary study, Cureus, 2025, PMID 40190969
Negative Study
Read the paper on PubMed →In contrast, iron concentrations and iron changes after FBC consumption did not significantly differ from the reference condition.
12 more not counted · see why
The study is not yet read in full. 11
- Controlled trial, Nutrition, 2001, PMID 11377130
- Other primary study, Arch Latinoam Nutr, 2001, PMID 11688077
- Trial or observed group, Dig Dis Sci, 2006, PMID 16642425
- Controlled trial, Clin Ther, 1991, PMID 1799918
- Controlled trial, Nutrition, 2008, PMID 18499399
- Controlled trial, Biomed Pharmacother, 2012, PMID 22795809
- Controlled trial, J Perinat Med, 2014, PMID 24152889
- Controlled trial, Biomedica, 2013, PMID 24652170
- Pooled analysis, Nutr Rev, 2023, PMID 36728680
- Controlled trial, J Nutr, 2023, PMID 37271416
- Trial or observed group, Daru, 2024, PMID 38740692
The study cited could not be identified. 1
Show the receipts from 11 sources
-
Controlled trial, Nutrients, 2022, PMID 35276810 Study · positive
One in particular, ferrous bisglycinate, has been demonstrated to have at least two-fold higher bioavailability and absorption compared to conventional iron salts, including ferrous sulfate and ferrous fumarate, while also resulting in improved oral tolerability during pregnancy [ 6 , 7 ].
-
Trial or observed group, Int J Vitam Nutr Res, 2004, PMID 15743019 Study · partly
Finally there is an urgent need for more rigorous efficacy trials designed to define the relative merits of amino acid chelates when compared with bioavailable iron salts such as ferrous sulfate and ferrous fumarate and to determine appropriate fortification levels
-
Controlled trial, Nutr J, 2014, PMID 25023784 Study · partly
There were no significant differences between the groups in the presentation of side effects potentially associated to iron supplementation.
-
Trial or observed group, Curr Pediatr Rev, 2018, PMID 29366419 Study · partly
In our patients, treatment with iron bisglycinate chelate demonstrated an equivalent haematopoietic response compared to iron sulfate when administered approximately at quarter of the dose: 0.75 mg/kg/day compared to 3 mg/kg/day.
-
Controlled trial, Curr Pediatr Rev, 2018, PMID 30280670 Study · partly
However, only the FeBC group showed a significant increase in MCH and ferritin levels compared to baseline.
-
Trial or observed group, Ann Hematol, 2020, PMID 31965272 Study · partly
Gain of Hb at 2 and 8 weeks revealed a higher median increase in both ferrous 2 and ferrous 4 groups.
-
Other primary study, J Trace Elem Med Biol, 2020, PMID 32653832 Study · partly
A 1 mo intervention with 3 minerals that included iron (36 mg/day) significantly raised ferritin values when the iron was bisglycinate (p < 0.05), but not when it was ferrous sulfate (p > 0.05).
-
Trial or observed group, Clin Nutr ESPEN, 2021, PMID 34857222 Study · partly
Side effects of drugs were higher in FeBC group than LF group, and higher in LF with iron group than FeBC group.
-
Controlled trial, J Pregnancy, 2024, PMID 39582678 Study · partly
Comparing the three iron formulas in doses that can prevent ID and IDA, ferrous bisglycinate 25 mg iron had the most favourable GI side effect profile, while ferrous fumarate 40 mg iron and ferrous sulphate 50 mg iron had somewhat higher but similar GI side effect profiles.
-
Other primary study, Wiad Lek, 2026, PMID 41759009 Study · partly
Dynamic analysis of clinical symptoms and haematologic indicators in both groups demonstrated a significant decrease in subjective complaints, accompanied by normalization of laboratory parameters, confirming the positive effects of the interventions.
-
Other primary study, Cureus, 2025, PMID 40190969 Study · negative
In contrast, iron concentrations and iron changes after FBC consumption did not significantly differ from the reference condition.